Phase 3
Completed N=47
Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome
Stroke · Excitotoxicity · Memantine
Source: ClinicalTrials.gov NCT02535611 ↗
Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) — 4.52; 5.75 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The researchers aim to investigate the effect of memantine on stroke outcome in a randomized double-blind placebo-controlled clinical trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) |
3.42; 4.4 | — |
| PRIMARY Investigation of Disability by Modified Rankin Scale (mRS) |
2.3; 2.3 | — |
| SECONDARY Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) |
3.42; 4.4 | — |
| SECONDARY Investigation of Disability by Modified Rankin Scale (mRS) |
2.3; 2.3 | — |
Eligibility Criteria
Inclusion Criteria
- Presentation at first 24hrs of disease onset
- Confirmation of ischemic stroke in MCA territory by imaging.
- Accepted consent form
Exclusion Criteria
- Allergy history to memantine
- Stage 4 -5 renal failure base on Acute Kidney Injury Network criteria
- Moderate to severe hepatic failure (Child-Pugh criteria, grade B and C)
- History of epilepsy
- History of dementia
- History of memantine use in recent 6 months
- Pregnancy or breastfeeding
- Severe drug adverse effects
Data sourced from ClinicalTrials.gov (NCT02535611). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.